Their flagship products, ProSomnus [IA] and MicrO2 Sleep and Snore Devices, are designed to improve compliance and mitigate side effects, resulting in excellent patient experiences and outcomes. ProSomnus is focused on commercializing clinically relevant products, supporting scientific research, and making dental sleep medicine a viable therapy for obstructive sleep apnea (OSA), which affects over 74 million Americans. Their patented devices are a comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy and have treated over 150,000 patients.